NAS10030,482+2.83%S&P7,765+1.49%GOLD$4,362−0.51%BTC$85,955−0.75%VIX14.66−1.41%live tape · as of 15:00 UTC
The Screen · Healthcare · Biotechnology
Veradermics, Incorporated
MANE · the NYSE · USD · Market cap $4.7B · 24 employees
Veradermics, Incorporated, a clinical-stage biopharmaceutical company, focused on developing novel therapeutics for dermatologic and aesthetic conditions.
FAIL · Does not pass the screen
112.80 USD
Screen close, 2026-09-21 · not a live quote
Screened 2026-09-21 · the tape above runs as of 15:00 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
PRICE · FAIR-VALUE RANGE1M3M6MYTD1Y3Y5Y
What this means: price 112.80 against the desk's fair-value range, base estimate 167.00, over the last year.
Positioning no disclosures inside 60 days, left as found
Options no verdict drawn today, left as found
Ethical does not pass the values gate
Price112.80 USD
Fair value167.00
Ethical score70.0/100
Our investment reviews on this name
2026-09-04Read Markdown102.80+9.7% to today
2026-08-05Read Markup111.32+1.3% to today ✓
2026-07-02Read Markdown96.07+17.4% to today
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Veradermics, Incorporated holds its Accumulation at $112.80. The statistical read favours the sellers, held for 2 days.
As held on the ledger · 2026-09-21
Phase
Accumulation
Quantitative state
The statistical read favours the sellers, held for 2 days
Price at the screen
$112.80
Valuation
N/A trailing · -36.83 forward price to earnings
Values screen
FAIL· score 70.0
The Workings
Five Screens, Shown in Full
Does not pass. Interest-bearing securities
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
0.00%
Below 33%
Interest-bearing debt is just 0.0% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
78.69%
Below 33%
Interest-bearing cash and securities are 78.7% of assets, above the one-third limit.
Fail
Receivables
15.08%
Below 49%
Money owed to the company is 15.1% of assets, under the 49% limit.
Pass
Revenue purity
Excluded
Below 5%
of revenue comes from non-compliant sources, over the 5% line.
Fail
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
Fair value range in USD, drawn from the 2026-09-21 screen. The gold marker is the market price at the same screen. A 48.0% margin of safety to the base estimate.
Third-party analyst targets: 6 covering, consensus Strong Buy. The average target sits +48% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-09-21 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Hair Loss Biotech Stumbles on Missing Numbers
Picture a clinic where patients line up for a new hair loss pill that does not yet exist. Veradermics sits at that early stage, a clinical developer with no sales, zero profit margin and a forward earnings multiple that sits at minus 36.5 times. The gap between its share price of 111 dollars and an analyst-derived fair value of 167 dollars looks attractive on paper, yet the opportunity rating stays at none.
We pass because the ethical screen returns insufficient data on standard financial ratios. Without those basics the business cannot be judged on cash generation, competitive edge or governance, even though six analysts call the stock a strong buy. Unknown moat and pre-revenue status simply add to the case for staying clear.
Biotech pipelines carry heavy odds of late-stage failure and dilution risk that can wipe out any apparent margin of safety. Currency moves and regulatory setbacks sit outside the numbers shown here. Analysis, not advice.
The risks · The things to watch: as a biotechnology name, trial and regulatory outcomes can move it sharply either way.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
MANE trades on the NYSE. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-09-04Markdown · changed$102.80-7.7%Entry 5
The framework has shifted from markup to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 7.7% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B. Technically it is momentum reading neutral. Our forward projection puts the odds of a 10% gain over the next month near 74%. The street (3 analysts) rates it strong buy, with a mean price target of $131. Insiders have been net sellers over the past quarter.
2026-08-05Markup · changed$111.32+15.9%Entry 4
The framework has shifted from markdown to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 15.9% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B. Technically it is momentum reading neutral. Our forward projection puts the odds of a 10% gain over the next month near 74%. The street (3 analysts) rates it strong buy, with a mean price target of $131.
2026-07-18Markdown$96.07+0.0%Entry 3
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B. Technically it is momentum reading neutral. Our forward projection puts the odds of a 10% gain over the next month near 74%. The street (3 analysts) rates it strong buy, with a mean price target of $131.
2026-07-03Markdown$96.07+0.0%Entry 2
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns.
2026-07-02Markdown$96.07Entry 1
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.